本帖最后由 老马 于 2013-3-13 13:43 编辑 ) O' z7 u) b! O" f4 M
6 i8 Q0 j( g% P2 L. l健择(吉西他滨)+顺铂+阿瓦斯汀
8 h4 c. b% i2 n: c Gemzar +Cisplatin + Avastin* h/ W* G! I) R/ |6 K- X2 x
http://annonc.oxfordjournals.org/content/21/9/1804.full, x2 r/ A* L2 V+ N( C" z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . E4 N u! I: `' H" b7 h" l
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 x9 o. M/ f# h8 d8 h% mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 s7 M6 A' O5 K3 G# U% V1 Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1028)
; H9 { w. x5 _3 i' D8 h8 b) S* N
华为网盘附件:4 }) X6 K" I' x- {
【华为网盘】ava.JPG
7 h! Q: b8 I" Y* P |